PHVS (Pharvaris NV) Moat Score: 4/10 (As of Jul. 11, 2026)


PHVS Pharvaris NV PHVS
22 GF Score
Price $35.02
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Moat Score?

Pharvaris NV PHVS -2.39% 22 Moat Score is 4 as of Jul. 11, 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,395 Biotechnology companies, Pharvaris NV ranks better than 88.75% on this metric.

Pharvaris NV has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Pharvaris NV has Narrow Moat: Pharvaris NV has a discernible but modest moat due to its focus on innovative drug development and some intellectual property. However, it lacks the market leadership and regulatory barriers needed for a stronger moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pharvaris NV might have Narrow Moat - Discernible but modest moat.

Pharvaris NV  (NAS:PHVS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pharvaris NV Moat Score Related Terms

PHVS vs BHVN, NRIX, VCEL: Moat Score Comparison

For the Biotechnology subindustry, Pharvaris NV's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Moat Score distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Moat Score falls into.


PHVS
22GF Score
Pharvaris NV PHVS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Pharvaris NV (PHVS) has a Moat Score of 4 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pharvaris NV ranks #157 out of 1395 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Pharvaris NV's Moat Score too high?
Pharvaris NV's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Pharvaris NV's value of 4 is 100% above this industry median. Based on the distribution chart, Pharvaris NV ranks #157 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Moat Score compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #157 out of 1395 companies for Moat Score. This places Pharvaris NV in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Pharvaris NV's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharvaris NV's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current Moat Score is 4 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.02
Price